ReviewEssays in biochemistry2021
3D bioprinting: novel approaches for engineering complex human tissue equivalents and drug testing.
Review in Essays in biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Feasible Regions of Nozzle Temperature, Extrusion Pressure, and Printing Speed in Extrusion-Based Printing Using a Sodium Alginate-Carboxymethylcellulose-Collagen I Bioink.Biomimetics (Basel, Switzerland) · 2026Article
- Seeing through collagen: integrative pro-regenerative corneal implants for clearer future.NPJ Regenerative medicine · 2026Review
- Three-Dimensional Bioprinting and Rose-Inspired Medical Applications.Biomimetics (Basel, Switzerland) · 2026Review
- AlternativeExpert reviews in molecular medicine · 2026Review
- Review
- Advances in Drug Delivery Integrated with Regenerative Medicine: Innovations, Challenges, and Future Frontiers.Pharmaceutics · 2025Review
- The Interface of Gene Editing with Regenerative Medicine.Engineering (Beijing, China) · 2025Article
- 3D bioprinting for the construction of drug testing models-development strategies and regulatory concerns.Frontiers in bioengineering and biotechnology · 2025Review
- 3D Bioprinting in Cancer Modeling and Biomedicine: From Print Categories to Biological Applications.ACS omega · 2024Review
- Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024Review
- Bioengineering breakthroughs: The impact of stem cell models on advanced therapy medicinal product development.World journal of stem cells · 2024Review
- Electron Spin Resonance Probe Incorporation into Bioinks Permits Longitudinal Oxygen Imaging of Bioprinted Constructs.Molecular imaging and biology · 2024Article
- 3D bioprinting of liver models: A systematic scoping review of methods, bioinks, and reporting quality.Materials today. Bio · 2024Article
- Improving tumor microenvironment assessment in chip systems through next-generation technology integration.Frontiers in bioengineering and biotechnology · 2024Review
- 3D Bioprinting in Microgravity: Opportunities, Challenges, and Possible Applications in Space.Advanced healthcare materials · 2023Article
- Generation of a Perfusable 3D Lung Cancer Model by Digital Light Processing.International journal of molecular sciences · 2023Article
- Toward better drug development: Three-dimensional bioprinting in toxicological research.International journal of bioprinting · 2023Review
- Evaluating the Suitability of 3D Bioprinted Samples for Experimental Radiotherapy: A Pilot Study.International journal of molecular sciences · 2022Article
- Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Conventional approaches in drug development involve testing on 2D-cultured mammalian cells, followed by experiments in rodents. Although this is the common strategy, it has significant drawbacks: in 2D cell culture with human cells, the cultivation at normoxic conditions on a plastic or glass surface is an artificial situation that significantly changes energy metabolism, shape and intracellular signaling, which in turn directly affects drug response. On the other hand, rodents as the most frequently used animal models have evolutionarily separated from primates about 100 million years ago, with significant differences in physiology, which frequently leads to results not reproducible in humans. As an alternative, spheroid technology and micro-organoids have evolved in the last decade to provide 3D context for cells similar to native tissue. However, organoids used for drug testing are usually just in the 50-100 micrometers range and thereby too small to mimic micro-environmental tissue conditions such as limited nutrient and oxygen availability. An attractive alternative offers 3D bioprinting as this allows fabrication of human tissue equivalents from scratch with hollow structures for perfusion and strict spatiotemporal control over the deposition of cells and extracellular matrix proteins. Thereby, tissue surrogates with defined geometry are fabricated that offer unique opportunities in exploring cellular cross-talk, mechanobiology and morphogenesis. These tissue-equivalents are also very attractive tools in drug testing, as bioprinting enables standardized production, parallelization, and application-tailored design of human tissue, of human disease models and patient-specific tissue avatars. This review, therefore, summarizes recent advances in 3D bioprinting technology and its application for drug screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.